<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04241718</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN06477</org_study_id>
    <nct_id>NCT04241718</nct_id>
  </id_info>
  <brief_title>A Feasibility Study on Ultrafiltration and Blood Volume Measurements</brief_title>
  <official_title>A Feasibility Study on Ultrafiltration and Blood Volume Measurements</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHF Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daxor Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CHF Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this feasibility study is to characterize the performance of CHF Solutions'
      ultrafiltration system, the Aquadex FlexFlow® System with the hematocrit (HCT) feature in
      conjunction with Daxor's blood volume analyzer (BVA-100). Monitor blood volume changes during
      UF therapy as a potential mean to guide the removal of fluid in subjects hospitalized with
      acute decompensated heart failure (ADHF).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Evaluate changes in blood volume as measured by BVA from before initiation until completion of extracorporeal fluid removal by ultrafiltration</measure>
    <time_frame>Through study procedure completion, average of 2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>2. Evaluate if changes in blood volume, as measured by BVA, correlate with changes in HCT as measured by the device embedded in the Aquadex FlexFlow System ultrafiltration device</measure>
    <time_frame>Through study procedure completion, average of 2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>3. Evaluate the temporal relationship between changes in blood volume, as measured by BVA , and changes in clinical signs and symptoms of fluid overload</measure>
    <time_frame>Through study procedure completion, average of 2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>4. Evaluate the temporal relationship between changes in HCT, as measured by Aquadex HCT, and changes in clinical signs and symptoms of fluid overload</measure>
    <time_frame>Through study procedure completion, average of 2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>5. Total net fluid loss prior to hospital discharge</measure>
    <time_frame>Daily during study procedure, average of 2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>6. Change in urinary sodium concentration from baseline to ultrafiltration completion</measure>
    <time_frame>Through study procedure completion, average of 2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>7. Change in biomarkers from baseline until discharge:</measure>
    <time_frame>through study completion, average of 2 weeks</time_frame>
    <description>Comprehensive Metabolic Panel (CMP)/Basic Metabolic Panel (BMP)
N-terminal proB- type natriuretic peptide (NT-proBNP)
Troponin-I
Urine Nephrocheck</description>
  </primary_outcome>
  <primary_outcome>
    <measure>8. Adverse events of special interest</measure>
    <time_frame>through study completion, average of 1 year</time_frame>
    <description>Acute coronary syndrome
Bleeding (requiring blood transfusion or drop of hemoglobin &gt;3g/dl)
Catheter-related bloodstream infections
Hypotension necessitating intervention</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <condition>Fluid Overload</condition>
  <arm_group>
    <arm_group_label>Single-arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No comparator, placebo, or randomization</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aquadex FlexFlow System and BVA-100</intervention_name>
    <description>Aquapheresis therapy with Aquadex FlexFlow System and Blood Volume Measurement with BVA-100</description>
    <arm_group_label>Single-arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or older

          2. Subject or legally authorized representative is able to provide appropriate consent to
             participate

          3. Hospitalized for ADHF with fluid overload as indicated by at least two of the
             following:

               1. Pitting edema ≥ 2+ of the lower extremities

               2. Jugular venous distention &gt; 8 cm

               3. Pulmonary edema/pleural effusion on chest x-ray

               4. Paroxysmal nocturnal dyspnea or ≥ two- pillow orthopnea

               5. Respiration rate ≥ 20 per minute

        Exclusion Criteria:

          1. Unable or unwillingness to provide informed consent or to comply with study
             requirements

          2. Subject who is pregnant

          3. Acute coronary syndrome

          4. Known bilateral renal artery stenosis

          5. Serum creatinine &gt; 3.0 mg/dL at the time of presentation

          6. Subject receiving ongoing active treatment with diuretics (up to 2 doses of IV
             diuretics are permitted before initiation of ultrafiltration therapy)

          7. Systolic blood pressure ≤ 90 mmHg

          8. Poor or unattainable central access

          9. Has bleeding disorder

         10. Contraindications to systemic anticoagulation

         11. Allergic to iodine, albumin, or iodinated I-131 albumin

         12. Active myocarditis or hypertrophic obstructive cardiomyopathy

         13. Severe uncorrected valvular stenosis

         14. Complex congenital heart disease

         15. Systemic infection

         16. Previous organ transplant

         17. Enrollment in other clinical trials

         18. Life expectancy ≤ 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Rosa Costanzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edward Hospital Center for Advanced Heart Failure</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Rosa Costanzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edward-Elmhurst Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Audrey Singh</last_name>
    <phone>952-345-4217</phone>
    <email>audrey.singh@chf-solutions.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Edward Hospital Center for Advanced Heart Failure</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60566</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stan Skaluba, MD</last_name>
      <phone>630-932-2165</phone>
    </contact>
    <contact_backup>
      <last_name>Maria Rosa Costanzo, MD</last_name>
      <phone>630-932-2165</phone>
    </contact_backup>
    <investigator>
      <last_name>Stan Skaluba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Rosa Costanzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Plan undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

